EUVIMEDEUVIMED entdecken
Crossref

Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer

Zheng Feng iD, Siyu Chen, Na An, Zhihui Xiu iD, Xingzhu Ju, Xiaojun Chen, Rui Bi, Jie Wang iD, Shida Zhu iD, Xiaohua Wu iD, Hao Wen iD

JCO Global Oncology · 2024

DOI: 10.1200/go.23.00454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Zheng Feng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Germ-Line Mutation, DNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Genetic variants of ovarian cancer (OV) show ethnic differences, but data from the Chinese population are still insufficient. Here, we elucidate the inheritance landscape in Chinese patients with OV and examine the functional implications of a Chinese-enriched RAD51D variant. METHODS Between 2015 and 2018, 373 consecutive patients with OV were prospectively enrolled. Variants of BRCA1/2, other homologous recombination repair (HRR) genes, and DNA mismatch repair (MMR) genes were analyzed using next-generation sequencing. An enriched RAD51D variant was identified, and its functional effects were examined using Cell Counting Kit-8, colony formation, transwell migration, and drug sensitivity assays. RESULTS Overall, 31.1% (116/373) of patients had at least one pathogenic or likely pathogenic germline variant. BRCA1 and BRCA2 accounted for 16.09% and 5.36%, respectively, with one patient having both variants. In addition, 32 (8.58%) patients carried other HRR gene variants, whereas three (0.8%) patients had MMR gene variants. The RAD51D variant ranked third (8/373, 2.1%), and its rate was much higher than that in other populations. Remarkably, all eight patients harbored the RAD51D K91fs variant (c.270_271dup, p.Lys91Ilefs*13) and demonstrated satisfactory platinum response and favorable prognosis. This variant confers enhanced sensitivity to poly (ADP-ribose) polymerase inhibitors in OV cells. However, the effects on platinum sensitivity were inconsistent across different cell lines. Against the background of the TP53 variant, RAD51D K91fs variant showed increased sensitivity to cisplatin. CONCLUSION Our study revealed the inheritance landscape of OV and identified an enriched RAD51D variant in Chinese patients with OV. This can serve as an important reference for OV management and a potential therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsGerm-Line MutationDNA-Binding ProteinsHumansFemaleMiddle AgedAdultAgedChinaProspective StudiesHigh-Throughput Nucleotide SequencingEast Asian People

Substanzen

RAD51D protein, humanDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • BGI Genomics, BGI-Shenzhen, Shenzhen, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.

ORCID-Profile: Zheng Feng, Zhihui Xiu, Jie Wang, Shida Zhu, Xiaohua Wu, Hao Wen

Zitieren

APA

Feng, Z., Chen, S., An, N., Xiu, Z., Ju, X., Chen, X., Bi, R., Wang, J., Zhu, S., Wu, X., & Wen, H. (2024). Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer. JCO Global Oncology. https://doi.org/10.1200/go.23.00454

Vancouver

Feng Z, Chen S, An N, Xiu Z, Ju X, Chen X, et al. Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer. JCO Global Oncology. 2024. doi:10.1200/go.23.00454

BibTeX
@article{Feng2024,
  author = {Feng, Zheng and Chen, Siyu and An, Na and Xiu, Zhihui and Ju, Xingzhu and Chen, Xiaojun and Bi, Rui and Wang, Jie and Zhu, Shida and Wu, Xiaohua and Wen, Hao},
  title = {Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.23.00454}
}
Kostenlos starten →